과제정보
This study was supported by the Basic Science Research Pro-gram through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (NRF-2015R1C1A1A01054591) (Yoon Ho Ko) and by The Catholic University of Korea Uijeongbu St. Mary's Hospital Clinical Research Laboratory Foundation made in the program year of 2013 (Yoon Ho Ko).
참고문헌
- Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009;45:309-316. https://doi.org/10.1016/j.oraloncology.2008.06.002
- Markovic A, Chung CH. Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma. Expert Rev Anticancer Ther 2012;12:1149-1159. https://doi.org/10.1586/era.12.91
- Carinci F, Stabellini G, Calvitti M, et al. CD44 as prognostic factor in oral and oropharyngeal squamous cell carcinoma. J Craniofac Surg 2002;13:85-89. https://doi.org/10.1097/00001665-200201000-00020
- McDonald JA, Camenisch TD. Hyaluronan: genetic insights into the complex biology of a simple polysaccharide. Glycoconj J 2002;19:331-339. https://doi.org/10.1023/A:1025369004783
- Itano N, Kimata K. Mammalian hyaluronan synthases. IUBMB Life 2002;54:195-199. https://doi.org/10.1080/15216540214929
- Stern R. Hyaluronan catabolism: a new metabolic pathway. Eur J Cell Biol 2004;83:317-325. https://doi.org/10.1078/0171-9335-00392
- Wang C, Tammi M, Guo H, Tammi R. Hyaluronan distribution in the normal epithelium of esophagus, stomach, and colon and their cancers. Am J Pathol 1996;148:1861-1869.
- Ropponen K, Tammi M, Parkkinen J, et al. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res 1998;58:342-347.
- Setala LP, Tammi MI, Tammi RH, et al. Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate. Br J Cancer 1999;79:1133-1138. https://doi.org/10.1038/sj.bjc.6690180
- Auvinen P, Tammi R, Parkkinen J, et al. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 2000;156:529-536. https://doi.org/10.1016/S0002-9440(10)64757-8
- Byers LA, Diao L, Wang J, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 2013;19:279-290. https://doi.org/10.1158/1078-0432.CCR-12-1558
- Lassen P, Primdahl H, Johansen J, et al. Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer. Radiother Oncol 2014;113:310-316. https://doi.org/10.1016/j.radonc.2014.11.032
- Li L, Asteriou T, Bernert B, Heldin CH, Heldin P. Growth factor regulation of hyaluronan synthesis and degradation in human dermal fibroblasts: importance of hyaluronan for the mitogenic response of PDGF-BB. Biochem J 2007;404:327-336. https://doi.org/10.1042/BJ20061757
- Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004;4:528-539. https://doi.org/10.1038/nrc1391
- Lokeshwar VB, Rubinowicz D, Schroeder GL, et al. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem 2001;276:11922-11932. https://doi.org/10.1074/jbc.M008432200
- Kosunen A, Ropponen K, Kellokoski J, et al. Reduced expression of hyaluronan is a strong indicator of poor survival in oral squamous cell carcinoma. Oral Oncol 2004;40:257-263. https://doi.org/10.1016/j.oraloncology.2003.08.004
- Hirvikoski P, Tammi R, Kumpulainen E, et al. Irregular expression of hyaluronan and its CD44 receptor is associated with metastatic phenotype in laryngeal squamous cell carcinoma. Virchows Arch 1999;434:37-44. https://doi.org/10.1007/s004280050302
- Kramer MW, Escudero DO, Lokeshwar SD, et al. Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer 2011;117:1197-1209. https://doi.org/10.1002/cncr.25565
- Tan JX, Wang XY, Su XL, et al. Upregulation of HYAL1 expression in breast cancer promoted tumor cell proliferation, migration, invasion and angiogenesis. PLoS One 2011;6:e22836. https://doi.org/10.1371/journal.pone.0022836
- McAtee CO, Barycki JJ, Simpson MA. Emerging roles for hyaluronidase in cancer metastasis and therapy. Adv Cancer Res 2014;123:1-34. https://doi.org/10.1016/B978-0-12-800092-2.00001-0
- Okuda H, Kobayashi A, Xia B, et al. Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem-like cells with macrophages and stromal cells. Cancer Res 2012;72:537-547. https://doi.org/10.1158/0008-5472.CAN-11-1678
- Lien HC, Lee YH, Jeng YM, et al. Differential expression of hyaluronan synthase 2 in breast carcinoma and its biological significance. Histopathology 2014;65:328-339. https://doi.org/10.1111/his.12390
- Zhang Z, Tao D, Zhang P, et al. Hyaluronan synthase 2 expressed by cancer-associated fibroblasts promotes oral cancer invasion. J Exp Clin Cancer Res 2016;35:181. https://doi.org/10.1186/s13046-016-0458-0
- Kang H, Kiess A, Chung CH. Emerging biomarkers in head and neck cancer in the era of genomics. Nat Rev Clin Oncol 2015;12:11-26. https://doi.org/10.1038/nrclinonc.2014.192
- Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517:576-582. https://doi.org/10.1038/nature14129
- Chung CH, Parker JS, Karaca G, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004;5:489-500. https://doi.org/10.1016/S1535-6108(04)00112-6
- Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012;21:418-429. https://doi.org/10.1016/j.ccr.2012.01.007
- Thompson CB, Shepard HM, O'Connor PM, et al. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther 2010;9:3052-3064. https://doi.org/10.1158/1535-7163.MCT-10-0470
- Sato N, Cheng XB, Kohi S, Koga A, Hirata K. Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma. Acta Pharm Sin B 2016;6:101-105. https://doi.org/10.1016/j.apsb.2016.01.002
- Hingorani SR, Zheng L, Bullock AJ, et al. HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. J Clin Oncol 2018;36:359-366. https://doi.org/10.1200/JCO.2017.74.9564